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Abstract 
 Syndecan-1 is a membrane proteoglycan, which is a protein with glycosaminoglycans, or 
long carbohydrate chains, attached to its extracellular domain. The syndecan family is composed 
of various proteoglycans that each aid in cell-to-cell communication, and cell signaling 
pathways. Syndecan-1 plays a role in the initiation and progression of many different types of 
cancer. The overall goal of our research is to express and isolate the human syndecan-1 protein 
in bacterial cells, and then proceed with glycosylation of the protein. In order to have effective 
expression and cleavage of syndecan-1, a His6-TrpΔLE fusion partner was attached to the 
syndecan-1 protein, and the sequence of syndecan-1 was altered to replace any cysteine and 
methionine residues with serine residues. The path to achieving this involves a growth of cells 
with emphasis on the expression of syndecan-1, a chemical cleavage of the TrpΔLE fusion 
partner from the syndecan-1 protein, purification by size-exclusion chromatography, and each 
step monitored by SDS-PAGE to show expression and purity. The syndecan-1 protein in its 
altered form weighs 31.903kDa, and the TrpΔLE weighs approximately 14kDa. We found that 
we were successful in cleavage and expression via SDS-PAGE, and got separation of protein 
through size-exclusion chromatography, but have not expressed a large amount of protein from 
growths, nor have we gotten proof of our protein expression by mass spectrometry. In the future, 
we plan on making slight adjustments in protocol and doing more growths to create more protein 
to work with, and find a reason that we are unable to identify the protein by mass spectrometry. 
Introduction 
 Syndecan-1 can serve as a signal for tumors and as a marker for multiple myeloma by its 
up-regulation within plasma cells of the bone marrow [1][2]. Even though it has been found to be 
in correlation with multiple myeloma, there is not much understanding of it in ways to be treated 
[1][2]. Myeloma is one cancer in which syndecan-1 enhances cell growth, but the presence of 
syndecan-1 in lung cancer and mesothelioma have actually been correlated with favorable results 
[3]. The seemingly contradictory relations of syndecan-1 from various studies illustrates exactly 
why the knowledge of the structure of syndecan-1 may be an important step in the treatment of 
cancers. The extracellular domain of syndecan-1 contains glycosaminoglycan groups such as 
heparan sulfate that are able to bind ligands. Examples of these ligands are growth factors, 
chemokines, or other cell stimulating agents, which all result in syndecan-1 upregulation. This 
syndecan-1 upregulation is observed in correlation with many cancers [3].  
Cancer Significance: The binding of growth factors or chemokines to the glycosaminoglycan 
chains associated with the extracellular domain of syndecan-1 serves to sequester these 
substrates in close proximity to their respective receptors. This relative closeness of growth 
factors to their receptor counterparts allows for their eventual binding [3]. Once a growth factor 
is bound to its designated receptor on the surface of the cell, it initiates a cascade of intracellular 
enzymes and reactions related to the extracellular-signal-regulated kinase (ERK) pathway, or 
more specifically, the mitogen activated protein kinase (MAPK) pathway. These cascades 
ultimately result in the production of matrix metalloproteases, which serve to cleave a portion of 
the syndecan-1 extracellular domain, with the location varying by the specific metalloprotease 
[3]. This cleaved portion of the extracellular domain still contains glycosaminoglycan chains 
capable of binding substrates, so its journey through the blood may trigger more intracellular 
cascades within cells of a different area of the body. In this way, syndecan-1 is able to propagate 
the effects of cell proliferation, as well as serve as a marker for possible cancer if the blood 
contains an abnormally large concentration of shed syndecan-1.  
Research: The goal of our project is to overexpress the syndecan-1 protein in the hopes of being 
able to isolate and work with a large amount of it. By overexpressing syndecan-1, we can 
characterize its structure, function, dynamics, and interactions in cell-like conditions. Once 
overexpression and isolation have been proven, the next step is to glycosylate the protein to see 
how it may affect its structure, and therefore, its function. Because syndecan-1 is a membrane 
protein, its overexpression in bacteria may cause instability of the membrane, so in order to 
alleviate this problem, a fusion partner named TrpΔLE was included in front of the syndecan-1 
sequence in the transformed plasmid. This partner causes the protein to aggregate into inclusion 
bodies within the cytosol, and thus prevents syndecan-1 from overburdening the cell membrane 
as it would ordinarily if overexpressed. This TrpΔLE fusion partner also contains a His6-tag for 
the utilization of nickel affinity chromatography if the protein should need further purification. 
Methods 
Plasmid 
 The pHLV plasmid was used to insert our TrpΔLE and syndecan-1 proteins. The specific 
insertion of syndecan-1 is between the HindIII and BamHI restriction endonucleases. This 
modified plasmid was then transformed into E. coli cells and grown in order to set up a 
permanent cell stock in the -80 degree Celsius freezer.  
Expression 
 E. coli cells containing the aforementioned transformed plasmid are grown in a 37 degree 
Celsius room starting in a 50mL tube containing 5mL of Luria Bertani (LB) medium, 10µL of 
cell stock, and 5µL of carbenicillin. This starter culture is grown for 2 hours before transferring 
400µL from it to each of two 250mL flasks containing 100mL of LB along with 100µL of 
carbenicillin. These 250mL flasks are grown for 14-16 hours and then 50mL is transferred to 
each of four 2L flasks containing 950mL of LB along with 1mL of carbenicillin. These flasks are 
grown and monitored until they reach an optical density of 0.6 at 600nm and then they are 
induced with 1 mL of isopropyl β-D-1 thiogalactopyranoside (IPTG). Following induction, the 
cells are grown for 4 hours and then pelleted via centrifugation and these pellets are stored at -80 
degrees Celsius. Carbenicillin is added at each transfer step to maintain purity due to the fact the 
plasmid we transformed into the bacteria containing our TrpΔLE-Syndecan-1 gene also contains 
the gene for carbenicillin resistance.  
Lysis 
 Resuspension 1 buffer is added to the frozen pellets, and this is sonicated to break open 
the cells. The resulting solution is centrifuged and the supernatant is removed. Then after the 
addition of resuspension 2 buffer to the pellet, we sonicate again, and that is followed by another 
centrifugation. Following centrifugation after resuspension 2 buffer, protein is dissolved for at 
least eight hours in binding buffer, sonicated, centrifuged, and then dialyzed in 5 liters of water 
for at least eight hours before placing the resulting precipitate on the lyophilizer.  
Cleavage 
  Chemical cleavage of syndecan-1 from TrpΔLE is achieved using cyanogen bromide, 
formic acid, and water. This is all added to a tube containing the protein and repeatedly inverted 
on a rocker without light exposure for three to three and a half hours. Following the completion 
of the reaction, sodium hydroxide is added to neutralize the solution. We then transfer the 
solution to dialysis tubing and place it in 4L of water followed by two water exchanges, one at 
30 minutes, and then another at one hour and 30 minutes. Once the dialysis is complete, we 
lyophilize our protein for use in the next steps. 
Purification via Size-Exclusion Chromatography 
 Fast protein liquid chromatography (FPLC) is used to separate syndecan-1 from the 
TrpΔLE protein. Using the lyophilized sample following cleavage, 25mg of protein is dissolved 
in 500µL of 10% SDS. Once the protein is dissolved, 1.5mL of water is added to the sample and 
then it is centrifuged to remove any non-dissolving protein. The solution is then taken up by a 
syringe and injected with a filter tip onto a 2mL loop of the FPLC machine. The machine then 
pumps FPLC SDS buffer pH 8.2 through the loop and onto the column. As protein runs through 
the column, a light of wavelength 280nm provides a chromatogram of peaks indicating the 
passage of protein through the column and into the fraction collection tubes. By analyzing the 
resulting chromatogram from a sample run via FPLC, we can locate which fraction tubes contain 
our protein. 
Mass Spectrometry Preparation 
 After isolating the syndecan-1 protein in fraction tubes via FPLC, we transfer the solution 
to dialysis tubing in water for precipitation. Then, the post-dialysis solution is centrifuged, and 
the resulting pellet is lyophilized before being ready for analysis by mass spectrometry. MALDI-
TOF is the typical mass spectrometry method used, and it requires the protein sample to be 
dissolved in an organic solvent, such as acetonitrile or tetrafluorethylene.  
Electrophoresis 
 We utilized SDS-PAGE for quantification of each step of the process including 
expression, lysis, cleavage, FPLC, and mass spectrometry. This consists of running a current 
through a gel that was loaded with our desired samples and a molecular weight standard.  
Results 
 The growth protocol has been successful based off gel runs with our pre- and post-
induction samples, which showed an obvious change in band thickness and color around the 
46kDa range with syndecan-1 being ~32kDa and the TrpΔLE at 14kDa. The exact molecular 
weight of our mutated syndecan-1 protein is 31,903Da. Following the cleavage step, the amount 
of protein obtained has ranged from 22-40mg. FPLC chromatograms have shown effective 
separation of various proteins by way of multiple peaks and their distance apart from one 
another. To improve separation of peaks in FPLC, we decided to run a double column setup, and 
the chromatogram relating to this can be seen in Figure 3. An SDS-PAGE of a post-FPLC 
dialysis sample revealed a thick protein band in the ~64kDa region. The below figures are 
relating to various steps of the protocol, with Figure 1 showing cleavage results, Figure 2 the 
single column FPLC chromatogram, Figure 3 the double column FPLC chromatogram, and 




Figure 1: SDS-PAGE showing cleavage of syndecan-1 
 
 
































Figure 3: Double column FPLC of syndecan-1 with syndecan-1 being the second peak in the ~240mL range (truncated due to 





























Figure 4: Mass spectrometry chromatogram of post-FPLC syndecan-1 sample 
Discussion 
 While we have evidence of expression of the syndecan-1 protein with the TrpΔLE after 
growth, it has not yielded a large enough amount to enable testing of different methods in terms 
of FPLC within the same growth. We had decided to run a gel of the resuspension samples, as 
outlined in the methods section, and the lanes containing the resuspension 1 and 2 supernatant 
samples show thick bands in the 46kDa region, which may mean that some of our protein is still 
soluble in the weak detergent. The second gel of the lysis samples did not show the same results 
as the previous one, due to a lack of band in the 46kDa region, so the lysis that was performed on 
the first gel may have been from errors made. As can be seen in Figure 1, there is still a lot of 
noise present in our FPLC-isolated fraction, and no indication of the expected 31,903Da 
syndecan-1 protein. The SDS-PAGE of the post-FPLC dialysis sample, which yielded a band in 
the 64kDa region, is likely representative of our syndecan-1 in the form of a dimer. Following 
cleavage, the syndecan-1 protein should be separate from the TrpΔLE, which would make it 
around 32kDa in mass. As a way to improve the separation of our protein peaks in FPLC, the 
protocol was altered to incorporate the utilization of a second column. This involves using 
600mL of buffer instead of 300mL, and doubles the running time, but the extended journey of 
the protein through a second column proved to space out the peaks on the chromatogram, and 
thus separated the fraction tubes containing different proteins. Even though cysteine and 
methionine residues have been removed from the sequence to avoid protein misfolding by way 
of disulfide bonds, the protein may still have hydrophobic interactions with other syndecan-1 
proteins, which can cause dimerization.  
Moving forward, we intend to add salt to our mass spectrometry-prepared protein sample to see 
if this can interrupt possible hydrophobic interactions, and leave us with syndecan-1 monomers. 
We also plan to try different types of mass spectrometry such as ElectroSpray ionization, and 
even different organic solvents for MALDI-TOF. If we are able to verify its structure and 
identity through mass spectrometry, we will then attempt to characterize its structure via nuclear 
magnetic resonance spectroscopy (NMR). Once we have accomplished this, the goal is to 
glycosylate the protein to see how its dynamics and function may be affected. With the use of a 
lipid environment-mimicking nanodisc, we would be able to view the protein and its protein-
protein interactions in conditions similar to a real cell.  
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